Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published.
Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract for a poster presentation at the ESMO Congress 2023 today has been published online on the ESMO website.
After the submission of the abstract, the data set to be included in the poster presentation on Monday 23 October was expanded. The majority of the patients are still early in the treatment course, and responses will continue to evolve.
Details for the poster session are as follows:
Abstract Title: Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: interim results from the ATLAS-IT-05 trial
Poster Number: 1051P
Session: Investigational immunotherapy
Session Date and Time: Monday, October 23, 2023
Session Location: Hall 8
Dr. Øystein Rekdal, Chief Executive Officer at Lytix Biopharma, commented: “The ATLAS-IT-05 study presents an opportunity to demonstrate whether LTX-315 in combination with pembrolizumab treatment could enhance the clinical outcome in PD-1 / PD-L1 refractory melanoma patients. We are looking forward to presenting interim data at ESMO even though this is very early in the study as the treatment cycles have not been completed for the majority of the patients included.”
For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager: ole.peter.nordby@lytixbiopharma.com
Optimum Strategic Communications: Nick Bastin, Vici Rabbetts: lytix@optimumcomms.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315`s dual mode of action allows cytotoxic T cells to infiltrate tumors and recognize and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors including PBM Capital, a US based, healthcare-focused investment firm.